tiprankstipranks
Trending News
More News >
VISEN Pharmaceuticals (HK:2561)
:2561
Hong Kong Market
Advertisement

VISEN Pharmaceuticals (2561) Income Statement

Compare
0 Followers

VISEN Pharmaceuticals Income Statement

Last quarter (Q2 2025), VISEN Pharmaceuticals's total revenue was ¥-880.50K, a decrease of 0.00% from previous quarter. In Q2, VISEN Pharmaceuticals's net income was ¥-59.01M. See VISEN Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22
Total Revenue
¥ 2.78M¥ -1.67M¥ -2.30M
Gross Profit
¥ 2.78M¥ -1.67M¥ -2.30M
Operating Expenses
¥ 174.18M¥ 138.83M¥ 358.29M
Depreciation and Amortization
¥ 4.47M¥ 7.00M¥ 7.40M
EBITDA
¥ -177.62M¥ -242.26M¥ -280.95M
Operating Income
¥ -174.18M¥ -138.83M¥ -358.29M
Other Income/Expenses
¥ -8.06M¥ -110.74M¥ 69.32M
Pretax Income
¥ -182.24M¥ -249.57M¥ -288.97M
Net Income
¥ -182.24M¥ -249.57M¥ -288.97M
Per Share Metrics
Basic EPS
¥ -1.95¥ -2.67¥ -3.09
Diluted EPS
¥ -1.95¥ -2.67¥ -3.09
Weighted Average Shares Outstanding
93.64M 93.64M 93.64M
Weighted Average Shares Outstanding (Diluted)
93.64M 93.64M 93.64M
Currency in CNY

VISEN Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis